Raymond James Downgrades Leap Therapeutics (LPTX) to Market Perform
Tweet Send to a Friend
Raymond James analyst David Novak downgraded Leap Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
